An enzyme-linked immunosorbent assay (ELISA) was developed for detecting antibodies against Trypanosoma cruzi. Two synthetic T. cruzi peptides, TcD and PEP2, were used. The specificity and sensitivity of the peptide ELISA were determined with 260 serum samples from individuals living in an area in which Chagas' disease is endemic. ELISAs were performed with the peptides singly or in combination. The evaluation of these tests showed that 168 (93.8%) of 179 serum samples from T. cruzi-infected patients were positive when TcD peptide was used as antigen; 164 (91.6%) samples were positive with PEP2, and 178 (99.4%) samples were positive when the two peptides were combined. Thus, the sensitivity of the ELISA using the two peptides exceeded 99%0o. The specificity was evaluated by using a panel of 118 serum samples that included samples from 81 individuals living in an area of endemicity with negative serology for Chagas' disease and from 37 patients from areas in which T. cruzi was not endemic but with other pathologies, such as leishmaniasis, tuberculosis, and leprosy. Only two false-positive serum samples were found in this group of individuals, giving a test specificity of more than 98%. Because these peptides can be synthesized and are very stable at room temperature, the use of such reagents can improve the standardization and reproducibility of ELISAs for the serodiagnosis of T. cruzi infection.
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Chagas' disease, caused by the parasite protozoan Trypanosoma cruzi, is a severe endemic infection affecting several million people in Central and South America. The most important route of transmission, in areas of endemicity, is still by contact of a human being with an infected triatomid bug. However, blood transfusion is the dominant means of transmission in areas in which the disease is not endemic (16, 17) . In view of this, screening of blood is mandatory for donors from both areas of endemicity and areas in which the disease is not endemic but in which a high migration of individuals from areas of endemicity occurs. The most specific way to diagnose T. cruzi infections is by detection of the parasite in blood samples by direct examination, hemoculture, or xenodiagnosis. However, these methods have a low sensitivity (less than 50%) and are time-consuming (2 (7, 8, 11, 14) . Evaluation of some of these defined antigens has shown promising results for the diagnosis of T. cruzi infection (6, 8, 13, 15) . With that approach, peptides have also been obtained and used as antigens in ELISAs (3, 19, 20) . Among the different peptides described, two (TcD and peptide 2) were shown to have high sensitivity and specificity in detecting specific antibodies in sera from T. cruzi-infected individuals. In previous studies, the TcD 
RESULTS
Sera from 260 individuals living in an area of endemicity for Chagas' disease were assayed by IFA, IHA, and ELISA for the diagnosis of T. cruzi infection. One hundred seventy-nine positive serum samples and 81 negative serum samples in all three tests were chosen for further study, using the TcD and PEP2 ELISA (Fig. 1) . From the data shown in Fig. 1 , the TcD ELISA was found to be 93% sensitive and the PEP2 ELISA was 91% sensitive. As observed in Table 1 , only one serum sample did not react with either peptide. In view of these results, an ELISA test using a mixture of both peptides was designed and evaluated. Using this assay, only one positive serum sample was missed, and the test was shown to have a sensitivity of greater than 99%. The specificity of the peptide test was evaluated with sera from individuals living in an area of endemicity for Chagas' disease who had negative T. cruzi serology, as well as with sera from patients with other pathologies. In these samples, 2 of 81 samples were positive, but no "EMBR, commercial ELISA from EMBRABIO.
Individuals from an area where Chagas' disease is endemic but with negative serology.
false-positive results were found among the 37 serum samples from individuals with other pathologies ( To overcome these problems, we developed and evaluated an ELISA that uses a mixture of two T. cruzi trypomastigotederived synthetic peptides as antigens. Initially, when TcD and PEP2 peptides were individually used as antigens in ELISAs, the sensitivities of the tests were 93 and 91%, respectively. These results are in agreement with previous data in which TcD showed 95% sensitivity (3) and PEP2 showed 92% sensitivity (20) . It should be pointed out that both peptides were described as having high specificity and showed no cross-reactivity with leishmaniasis patient sera. These sera are considered one of the most commonly cross-reactive groups in the IFA (5, 9) . We obtained similar results, although two serum samples from patients without Chagas' disease showed positive results with TcD and one sample was positive with PEP2. Other peptides have been used as antigens for the diagnosis of T. cruizi infection, but their sensitivities in detecting specific antibodies were shown to be lower than those of the peptides evaluated in this study (19) . Considering these results, we decided to combine the TcD and PEP2 peptides and use them as a single antigen in an ELISA. The use of a mixture of defined antigens in an ELISA for the serodiagnosis of Chagas' disease has been tested before with two recombinant antigens, CRA and FRA (13) . In this case, the test showed 100% sensitivity and 100% specificity. However, a mixture of synthetic peptides was not tested, although reports have suggested that a combination of synthetic peptides would increase the sensitivity in detecting most of infected patients (19) . With a combination of TcD and PEP2 peptides, we found high levels of sensitivity (99.7%) and specificity (99%). The only serum sample that showed a false-negative result was obtained from a patient who had received specific treatment for Chagas' disease. This serum sample also showed a weak positive reaction in the commercial ELISA test and IFA (1:40) . It has been documented that after specific treatment antibody responses to T crulzi antigens can decrease, and sometimes conventional serological tests become negative (12, 18) .
Recombinant polypeptides are powerful reagents for serological diagnosis, mainly due to the larger spectrum of epitopes on their structure. However, synthetic peptides can be very useful because they can be readily produced in large amounts and standardized. Our results demonstrate the applicability of two well-defined synthetic peptides, particularly when used in combination, to the diagnosis of Chagas' disease. Their use in an ELISA would be important because of their stability, reproducibility, and reliability.
